Literature DB >> 23434735

Chimerism and use of mesenchymal stem cells in umbilical cord blood transplantation.

Sofia Berglund1, Michael Uhlin, Jonas Mattsson.   

Abstract

We performed a retrospective single-center analysis of 50 umbilical cord blood transplantations (UCBTs), focusing on chimerism development. Complete donor chimerism (DC) was associated with acute graft-vs.-host disease (aGVHD) grades II-IV for the CD3 (+) cell lineage (p = 0.01) and, in multivariate analysis, with total body irradiation (TBI) for all lineages (p < 0.01). Overall survival (OS) was negatively associated with patient age, (p < 0.001); aGVHD grades III-IV, (p < 0.001); and treatment with mesenchymal stem cells (MSCs) (p = 0.027). In conclusion, though multiple factors may have contributed, the association of TBI and DC might be worthy of consideration in the treatment of patients with malignant disease in the UCBT setting. The negative influence of MSCs on OS may be a reason for more careful usage of this treatment modality in combination with UCBT.

Entities:  

Keywords:  HSCT; chimerism; hematological malignancy; mesenchymal stem cells; non-malignant disease; umbilical cord blood transplantation

Mesh:

Year:  2013        PMID: 23434735      PMCID: PMC3654738          DOI: 10.4161/chim.24073

Source DB:  PubMed          Journal:  Chimerism        ISSN: 1938-1964


  17 in total

Review 1.  Mixed chimerism in SCT: conflict or peaceful coexistence?

Authors:  J L Liesveld; P G Rothberg
Journal:  Bone Marrow Transplant       Date:  2008-07-28       Impact factor: 5.483

2.  Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease.

Authors:  Olle Ringdén; Mehmet Uzunel; Ida Rasmusson; Mats Remberger; Berit Sundberg; Helena Lönnies; Hanns-Ulrich Marschall; Aldona Dlugosz; Attila Szakos; Zuzana Hassan; Brigitta Omazic; Johan Aschan; Lisbeth Barkholt; Katarina Le Blanc
Journal:  Transplantation       Date:  2006-05-27       Impact factor: 4.939

3.  T cell mixed chimerism is significantly correlated to a decreased risk of acute graft-versus-host disease after allogeneic stem cell transplantation.

Authors:  J Mattsson; M Uzunel; M Remberger; O Ringdén
Journal:  Transplantation       Date:  2001-02-15       Impact factor: 4.939

Review 4.  A meta-analysis of unrelated donor umbilical cord blood transplantation versus unrelated donor bone marrow transplantation in adult and pediatric patients.

Authors:  William Ying Khee Hwang; Miny Samuel; Daryl Tan; Liang Piu Koh; Winston Lim; Yeh Ching Linn
Journal:  Biol Blood Marrow Transplant       Date:  2007-02-15       Impact factor: 5.742

5.  Transplantation of ex-vivo culture-expanded parental haploidentical mesenchymal stem cells to promote engraftment in pediatric recipients of unrelated donor umbilical cord blood: results of a phase I-II clinical trial.

Authors:  M L Macmillan; B R Blazar; T E DeFor; J E Wagner
Journal:  Bone Marrow Transplant       Date:  2008-10-27       Impact factor: 5.483

6.  Dose study of thymoglobulin during conditioning for unrelated donor allogeneic stem-cell transplantation.

Authors:  Mats Remberger; Britt-Marie Svahn; Jonas Mattsson; Olle Ringdén
Journal:  Transplantation       Date:  2004-07-15       Impact factor: 4.939

7.  Factors with an impact on chimerism development and long-term survival after umbilical cord blood transplantation.

Authors:  Sofia Berglund; Katarina Le Blanc; Mats Remberger; Jens Gertow; Mehmet Uzunel; Petter Svenberg; Jacek Winiarski; Per Ljungman; Olle Ringdén; Michael Uhlin; Jonas Mattsson
Journal:  Transplantation       Date:  2012-11-27       Impact factor: 4.939

8.  Stable mixed donor-donor chimerism after double cord blood transplantation.

Authors:  Sofia Berglund; Mantas Okas; Jens Gertow; Michael Uhlin; Jonas Mattsson
Journal:  Int J Hematol       Date:  2009-08-22       Impact factor: 2.490

9.  Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study.

Authors:  Katarina Le Blanc; Francesco Frassoni; Lynne Ball; Franco Locatelli; Helene Roelofs; Ian Lewis; Edoardo Lanino; Berit Sundberg; Maria Ester Bernardo; Mats Remberger; Giorgio Dini; R Maarten Egeler; Andrea Bacigalupo; Willem Fibbe; Olle Ringdén
Journal:  Lancet       Date:  2008-05-10       Impact factor: 79.321

10.  Results of a pilot study on the use of third-party donor mesenchymal stromal cells in cord blood transplantation in adults.

Authors:  Rosa Gonzalo-Daganzo; Carmen Regidor; Trinidad Martín-Donaire; Miguel Angel Rico; Guiomar Bautista; Isabel Krsnik; Rafael Forés; Emilio Ojeda; Isabel Sanjuán; Jose A García-Marco; Belen Navarro; Santiago Gil; Rocio Sánchez; Nuria Panadero; Yolanda Gutiérrez; Miguel García-Berciano; Nuria Pérez; Isabel Millán; Rafael Cabrera; Manuel N Fernández
Journal:  Cytotherapy       Date:  2009       Impact factor: 5.414

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.